+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Venture Capital Investment Trends in Pharma - Q3 2026

  • PDF Icon

    Report

  • 22 Pages
  • October 2026
  • Region: Global
  • GlobalData
  • ID: 6182038

Venture Capital Investment Trends in Pharma - Q3 2026

Summary

This report analyzes the venture capital (VC) investment activity in Q3 2026 in the Pharma sector.

Key Highlights

  • In Q3 2026, Global pharma investment totalled $6.3 billion, down 33% from Q2 2026. Deal volume fell 18.5% quarter over quarter to 154 transactions. Oncology ranked as the top therapy area, with 70 deals backed by 273 investors.

Scope

  • This report provides an overview of VC investment activity globally in Q3 2026 in the Pharma sector involving biopharmaceutical drug companies.
  • It identifies key trends, and the most notable deals announced in Q3 2026 in the Pharma sector.

Reasons to Buy

  • Companies that strategically invest in venture funding position themselves for success, while those that fail to adapt risk falling behind.
  • This report provides an overview of global VC investment trends in the pharma sector from the past quarter, offering insights into the industry landscape and key market movements.

Table of Contents

  • About the Analyst
List of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Pharma VC Investment Trends in Q3 2026

3 Global Investment Trends in Pharma

4 Global Quarterly Funding Activity in Pharma

5 Global VC Investment Trends for Biotechs

6 Top VC Investments in Pharma Q3 2026

7 Global Mega VC Investment Trends in Pharma

8 Global Quarterly Mega VC Investment Trends in Pharma

9 Global VC Investment in Pharma by Deal Size Analysis

10 Global VC Investment in Pharma by Funding Stage Analysis

11 Global VC Investment Trends in Pharma by Top Deal Stage

12 Regional VC Investment Comparison in Pharma - Q3 2026

13 Regional VC Investment in Pharma by Value and Volume

14 VC Investment Analysis in Pharma by Top 10 Countries

15 VC Investment Analysis in Pharma by 10 Therapy Areas

16 Top VC Investors in Pharma by Value in Q3 2026

17 Further Information
17.1 Methodology

18 Contact Us


List of Tables
Table 1: Top VC Investments in Pharma Q3 2026
Table 2: Regional VC Investment in Pharma by Value and Volume
Table 3: Top VC Investors in Pharma by Value in Q3 2026

List of Figures
Figure 1: Pharma VC Investment Analysis in Q3 2026
Figure 2: Global VC Investment Trends in Pharma
Figure 3: Global Quarterly Funding Activity in Pharma
Figure 4: Global VC Investment Trends for Biotechs
Figure 5: Global Mega VC Investment Trends in Pharma
Figure 6: Global Quarterly Mega VC Investment Trends in Pharma
Figure 7: Global VC Investment in Pharma by Deal Size Analysis
Figure 8: Global VC Investment in Pharma by Funding Stage Analysis
Figure 9: Global VC Investment Trends in Pharma by Top Deal Stage
Figure 10: Regional VC Investment Comparison in Pharma - Q3 2026
Figure 11: Regional VC Investment in Pharma by Value and Volume
Figure 12: VC Investment Analysis in Pharma by Top 10 Countries
Figure 13: VC Investment Analysis in Pharma by Top 10 Therapy Areas

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AdvanCell Isotopes
  • Anew Labs
  • Encoded Therapeutics
  • Solstice Oncology
  • LifeMine Therapeutics
  • Celea Therapeutics
  • Biossil
  • Vaderis Therapeutics
  • Basecamp Research
  • Crystalys Therapeutics
  • Circle Pharma
  • InduPro
  • Claris Biotherapeutics
  • Expedition Therapeutics
  • Epicrispr Biotechnologies
  • Moonwalk Biosciences
  • Engine Biosciences
  • Sling Therapeutics
  • Innovent Biologics